1.ARMENIA, D. et al. HIV Drug Resistance Remains a Relevant Clinical Concern, Despite its Dramatic Drop over the Years. In: 16th EACS. Milan, Italy, 2017. Parallel Session. Polypharmacy/HIV and HCV Resistance. 26.10.2017, 10:00 – 12:00. PS3/2. Disponível em: <http://www.professionalabstracts.com/eacs2017/iplanner/#/grid>. Acesso em: 26 out. 2017.
2.BEYRER, C. et POZNIAK, A. HIV Drug Resistance — An Emerging Threat to Epidemic Control. N Engl J Med 377;17:1605-1607, 2017.
3.MARCELLIN, AG. et al. French National Survey of Resistance to Integrase Inhibitors in a Context of Routine Hospital Care. In: 16th EACS. Milan, Italy, 2017. Parallel Session. Polypharmacy/HIV and HCV Resistance. 26.10.2017, 10:00 – 12:00. PS3/1. Disponível em: <http://www.professionalabstracts.com/eacs2017/iplanner/#/grid>. Acesso em: 26 out. 2017.
4.EUROPEAN AIDS CLINICAL SOCIETY. Guidelines. Version 9.0. Disponível em: <http://www.eacsociety.org/files/guidelines_9.0-english.pdf>. Acesso em: 26 out. 2017.
5.ORLANDI, C. et al. HIV-1 DNA as Marker to Monitor Reservoir in HIV-1 Patients. In: 16th EACS. Milan, Italy, 2017. Parallel Session. Science at the Bedside. 26.10.2017, 14:00 – 16:00. PS6/1. Disponível em: <http://www.professionalabstracts.com/eacs2017/iplanner/#/grid>. Acesso em: 26 out. 2017.
6.RUTSAERT, S. et al. HIV DNA as a Predictive Marker for Virologic Failure of Darunavir/r Monotherapy: A Substudy of the PROTEA Trial to Define a Cut-off for Success. In: 16th EACS. Milan, Italy, 2017. Parallel Session. Science at the Bedside. 26.10.2017, 14:00 – 16:00. PS6/2. Disponível em: <http://www.professionalabstracts.com/eacs2017/iplanner/#/grid>. Acesso em: 26 out. 2017.